Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

about

Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q38672091

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current and developing synthet ...... d/refractory multiple myeloma.

@en

type

Item

label

Current and developing synthet ...... d/refractory multiple myeloma.

@en

prefLabel

Current and developing synthet ...... d/refractory multiple myeloma.

@en

P1476

Current and developing synthet ...... d/refractory multiple myeloma.

@en

P2093

Klaus Podar

http://www.w3.org/2001/XMLSchema#string

Martin Pecherstorfer

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Targeting the BRAF V600E mutation in multiple myeloma.

PD-1 and its ligands in tolerance and immunity

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

P304

1061-1079

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1340942

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28604120

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy